Biotech: Page
-
News roundup
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
By Ben Fidler • Sept. 30, 2026 -
An AI agent made a tiny drug R&D mistake. Then it kept going.
The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What happens when a wrong answer becomes the basis for the next decision?
By Sy Mukherjee • Sept. 30, 2026 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Gene editing
Beam sues 2 biotechs, alleging theft of base editing trade secrets
Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges.
By Gwendolyn Wu • Sept. 29, 2026 -
Obesity drugs
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.
By Jonathan Gardner • Sept. 29, 2026 -
UniQure tumbles with latest data for Huntington’s gene therapy
Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."
By Jacob Bell • Sept. 29, 2026 -
Immune reset
ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’
Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.
By Gwendolyn Wu • Sept. 29, 2026 -
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.
By Ben Fidler • Sept. 29, 2026 -
Kodiak skyrockets on positive study data for 2 eye drugs
The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
By Jonathan Gardner • Sept. 28, 2026 -
This week in charts
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
The latest installment in BioPharma Dive’s data visualization series features a closer look at Novo's stock performance and the recent run of fundraising success for AI drug discovery startups.
By Gwendolyn Wu • Sept. 25, 2026 -
News roundup
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
By Ben Fidler • Sept. 25, 2026 -
IPO window
RNAi drug specialist ADARx raises $446M IPO
ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.
By Gwendolyn Wu • Sept. 24, 2026 -
News roundup
Lilly’s latest China drug deal; Immunovant’s setback in lupus
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.
By Ben Fidler • Sept. 24, 2026 -
Emerging biotech
Enveda, an AI drugmaker, banks $311M in venture funding
Enveda, which is using AI tools to mine plants and microbes for drug prospects, has three candidates in human testing for immune diseases and obesity.
By Gwendolyn Wu • Sept. 23, 2026 -
China competition
9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe
Frustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”
By Kristin Jensen • Sept. 23, 2026 -
Obesity drugs
Viking shares surge on updated obesity drug data
Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote.
By Jonathan Gardner • Sept. 22, 2026 -
News roundup
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
By Ben Fidler • Sept. 22, 2026 -
Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
Worth $1.65 billion up front, the deal combines two large pipelines and manufacturing networks, helping Telix potentially “corner the industry” for radiopharmaceuticals, one analyst wrote.
By Ben Fidler • Sept. 21, 2026 -
Q&A // Brain drug revival
How J&J paved the way for Compass’ coming psychedelic drug launch
In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato.
By Jacob Bell • Sept. 21, 2026 -
Xenon shares fall following depression trial pause
The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.
By Jonathan Gardner • Sept. 18, 2026 -
This week in charts
This week in charts: GSK’s China deals, the $300M IPO club and selling the news
The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.
By Ben Fidler • Sept. 18, 2026 -
News roundup
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
By BioPharma Dive staff • Sept. 18, 2026 -
IPO window
Electra amasses $350M in biotech’s latest big IPO
Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to BioPharma Dive data.
By Gwendolyn Wu • Sept. 17, 2026 -
Lisata deal propels Marea’s drug pipeline to Wall Street
Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.
By Delilah Alvarado • Sept. 17, 2026 -
Obesity drugs
Novo partners with Orbis, deepening investment in oral peptide drugs
The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.
By Jonathan Gardner • Sept. 17, 2026 -
Emerging biotech
North Immunology joins biotech reverse merger boom with Aethlon deal
Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.
By Kristin Jensen • Sept. 17, 2026